Anti-S100A4 antibody therapy is efficient in treating aggressive prostate cancer and reversing immunosuppression: Serum and biopsy S100A4 as clinical predictor.
S100A4 oncoprotein plays a critical role during prostate cancer (CaP) progression and induces immunosuppression in host-tissues. We hypothesized that S100A4 activity in immunosuppressed prostate tumors promotes the growth of neoplastic cells which are likely to become aggressive.
